Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Idarucizumab reversed dabigatran despite severe renal dysfunction

Eikelboom JW et al. ACC 18, the annual meeting of the American College of Cardiology, Abstract 1231M-11.

Key clinical point: Renal function had no impact on idarucizumab’s efficacy for dabigatran reversal.

Major finding: Complete dabigatran reversal occurred in 98% of patients with severe renal dysfunction who received idarucizumab.

Study details: Post hoc analysis of data from RE-VERSE AD, idarucizumab’s pivotal trial with 503 patients.

Disclosures: RE-VERSE AD was funded by Boehringer Ingelheim, the company that markets idarucizumab (Praxbind) and dabigatran (Pradaxa). Dr. Eikelboom has been a consultant to and has received research support from Boehringer Ingelheim, as well as from Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Janssen, and Pfizer.

Source: Eikelboom JW et al. ACC 18, the annual meeting of the American College of Cardiology, Abstract 1231M-11.

Read the article.

Citation:

Eikelboom JW et al. ACC 18, the annual meeting of the American College of Cardiology, Abstract 1231M-11.

This Week's Must Reads

Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005

Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04

TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885

Thrombolysis for acute ischemic stroke safe in GI malignancy, Inohara T et al. Circulation. 2018 Nov 6;138[suppl 1], Abstract A12291

Must Reads in Bleeding Disorders

FDA draft guidance on platelet safety, FDA Draft Guidance, December 2018

HemoTypeSC offers rapid sickle cell detection, Serrao E et al. ASH 2018, Abstract LBA-3

Impact of RBC transfusion limits, Roubinian NH et al. Ann Intern Med. 2018 Dec 18. doi: 10.7326/M17-3253

Early results for novel hemophilia A infusion, Chowdary P et al. ASH 2018, Abstract 489

Diagnostic challenges in hemophilia A, Patil R et al. Thromb Res. 2018 Dec;172:29-35